| Dr Michael Tyrone Morris Ii, MD | |
|
1150 Lake Hearn Dr Ste 500, Atlanta, GA 30342-1570 | |
| (404) 796-7011 | |
| (404) 796-7099 |
| Full Name | Dr Michael Tyrone Morris Ii |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 23 Years |
| Location | 1150 Lake Hearn Dr Ste 500, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245409101 | NPI | - | NPPES |
| 179651610H | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 232159 (New York) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 060941 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emory Decatur Hospital | Decatur, GA | Hospital |
| Emory Hillandale Hospital | Lithonia, GA | Hospital |
| Saint Joseph's Hospital Of Atlanta, Inc | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlanta Heart Specialists Llc | 9537134341 | 16 |
News Archive
Boston Scientific Corporation has announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.
Women "bea[r] the brunt" of weather-related disasters, but they also are "the key to stopping global warming, and to helping communities around the world adapt to the damage that has already been done," Mary Pittman, president and CEO of the Public Health Institute (PHI), and Kavita Ramdas, executive director of Stanford University's Program on Social Entrepreneurship, write in this post on "RH Reality Check."
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).
Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.
› Verified 6 days ago
| Entity Name | The Emory Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
Boston Scientific Corporation has announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.
Women "bea[r] the brunt" of weather-related disasters, but they also are "the key to stopping global warming, and to helping communities around the world adapt to the damage that has already been done," Mary Pittman, president and CEO of the Public Health Institute (PHI), and Kavita Ramdas, executive director of Stanford University's Program on Social Entrepreneurship, write in this post on "RH Reality Check."
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).
Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.
› Verified 6 days ago
| Entity Name | Atlanta Heart Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891881827 PECOS PAC ID: 9537134341 Enrollment ID: O20040826000416 |
News Archive
Boston Scientific Corporation has announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.
Women "bea[r] the brunt" of weather-related disasters, but they also are "the key to stopping global warming, and to helping communities around the world adapt to the damage that has already been done," Mary Pittman, president and CEO of the Public Health Institute (PHI), and Kavita Ramdas, executive director of Stanford University's Program on Social Entrepreneurship, write in this post on "RH Reality Check."
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).
Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.
› Verified 6 days ago
| Entity Name | Atlanta Vanguard Medical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164773164 PECOS PAC ID: 7810148368 Enrollment ID: O20121112000045 |
News Archive
Boston Scientific Corporation has announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.
Women "bea[r] the brunt" of weather-related disasters, but they also are "the key to stopping global warming, and to helping communities around the world adapt to the damage that has already been done," Mary Pittman, president and CEO of the Public Health Institute (PHI), and Kavita Ramdas, executive director of Stanford University's Program on Social Entrepreneurship, write in this post on "RH Reality Check."
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).
Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Tyrone Morris Ii, MD 1468 Montreal Rd, Tucker, GA 30084-6901 Ph: (770) 638-1400 | Dr Michael Tyrone Morris Ii, MD 1150 Lake Hearn Dr Ste 500, Atlanta, GA 30342-1570 Ph: (404) 796-7011 |
News Archive
Boston Scientific Corporation has announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.
Women "bea[r] the brunt" of weather-related disasters, but they also are "the key to stopping global warming, and to helping communities around the world adapt to the damage that has already been done," Mary Pittman, president and CEO of the Public Health Institute (PHI), and Kavita Ramdas, executive director of Stanford University's Program on Social Entrepreneurship, write in this post on "RH Reality Check."
PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).
Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.
› Verified 6 days ago
Khadeja Jamilia Johnson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1800 Howell Mill Rd Nw Ste 275, Atlanta, GA 30318 Phone: 404-756-1290 | |
Dr. Matthew J. Wilson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 755 Mt Vernon Hwy, Suite 530, Atlanta, GA 30328 Phone: 404-252-7970 Fax: 404-250-0553 | |
Kajal Patel, M.D, M.P.H Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1525 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-778-2700 | |
Dr. Earl Stewart Jr., M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2850 Paces Ferry Rd Se Ste 460, Atlanta, GA 30339 Phone: 678-556-4950 | |
Mary E. Bergh, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 980 Johnson Ferry Rd Ste 520, Atlanta, GA 30342 Phone: 404-303-3320 Fax: 404-303-3464 | |
John J Doran, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1365 Clifton Rd Ne Bldg A, The Emory Clinic - Nephrology, Atlanta, GA 30322 Phone: 404-778-5380 | |
Frank A Anania, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1365 Clifton Rd Ne Ste B1266, The Emory Clinic - Gastroenterology, Atlanta, GA 30322 Phone: 404-778-3184 |